Skip to main content

Advertisement

Table 1 Clinicopathological and molecular data of patients with differentiated thyroid cancer (DTC) included in the study

From: CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension

  Total FTC FVPTC PTC
Total (%) 98 (100) 15 (15.3) 23 (23.5) 60 (61.2)
Age (n) 98 15 23 60
 Mean (years) 43 ± 1.6 53 ± 3.9 43 ± 3.1 40 ± 2.1
Tumour size (n) 93 15 22 56
 Mean (cm) 2.8 ± 0.18 3.9 ± 0.46 2.4 ± 0.30 2.7 ± 0.24
Gender (n) 98 15 23 60
 Female (%) 84 (85.7) 12 (80) 19 (82.6) 53 (88.3)
 Male (%) 14 (14.3) 3 (20) 4 (17.4) 7 (11.7)
Capsule (n) 88 15 21 52
 Positive (%) 45 (51.1) 15 (100) 9 (42.9) 21 (40.4)
Capsular invasion (n) 42 15 8 19
 Positive (%) 27 (64.3) 15 (100) 2 (25.0) 10 (52.6)
Vascular invasion (n) 89 15 21 53
 Positive (%) 48 (53.9) 11 (73) 5 (23.8) 32 (60.4)
Lymph node metastasis (n) 93 15 21 57
 Positive (%) 24 (25.8) 4 (19.0) 20 (35.1)
Extrathyroidal extension (n) 88 15 21 52
 Positive (%) 27 (30.7) 1 (6.67) 2 (9.52) 24 (46.2)
Distant metastasis (n) 93 15 21 57
 Positive (%) 5 (5.38) 1 (6.67) 4 (7.02)
Lymphocytic thyroiditis (n) 91 15 22 54
 Positive (%) 40 (44.0) 4 (26.7) 8 (36.4) 28 (51.9)
Oncocytic (n) 89 15 21 53
 Positive (%) 17 (19.1) 6 (40.0) 11 (20.8)
PAX8-PPARG rearrangements (n) 98 15 23 60
 Positive (%) 2 (2.04) 1 (6.67) 1 (4.35)
RET/PTC rearrangements (n) 98 15 23 60
 Positive (%) 17 (17.3) 1 (6.67) 3 (13.0) 13 (21.7)
RET/PTC1 rearrangement (n) 98 15 23 60
 Positive (%) 12 (12.2) 1 (6.67) 1 (4.35) 10 (16.7)
RET/PTC3 rearrangement (n) 98 15 23 60
 Positive (%) 2 (2.04) 1 (4.35) 1 (1.67)
BRAF mutation (n) 98 15 23 60
 Positive (%) 21 (21.4) 2 (8.70) 19 (31.7)
NRAS mutation (n) 98 15 23 60
 Positive (%) 16 (16.3) 5 (33.3) 5 (21.7) 6 (10.0)
TERT promoter mutation (n) 98 15 23 60
 Positive (%) 3 (3.06) 2 (13.3) 1 (4.35)
  1. n, number of cases with available data
  2. FTC, follicular thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; PTC, papillary thyroid carcinoma